FrancophonIA/ELRC3.0 huggingface dataset:
English: The polymethacrylate is a polymer that forms a continuous film when processed.
Estonian: Polümetakrülaat on polümeer, mis moodustab töötlemisel pideva kile.
English: No adverse events have been reported for Ethirfin and associated names suspect to be related to the concomitant use of alcohol.
Estonian: Ethirfini ja sarnaste nimetuste korral ei ole teatatud kõrvalnähtudest, mis võivad olla seotud alkoholi samaaegse tarvitamisega.
English: The dissolution test method used was the routine test, i.e. paddle apparatus at 100 rpm with 1000 ml of medium.
Estonian: Lahustumiskatse tehti rutiinsel meetodil, kus kasutati 100 p/min pöörlevat labasegurit ja 1000 ml vedelikku.
English: The polymethacrylate preparation is miscible in water and in ethanol.
Estonian: Polümetakrülaadi preparaat seguneb vee ja etanooliga.
English: The amount of pain at baseline was a significant predictive factor for alcohol use in the 3-years follow-up period.
Estonian: Enne uuringut esinenud valu tugevuse järgi võis prognoosida alkoholitarbimist 3-aastase jälgimisperioodi jooksul.
English: Both problem drinkers and non-problem drinkers were included.
Estonian: Probleemsed alkoholitarbijad Mitteprobleemsed alkoholitarbijad
English: Triethylcitrate is water-soluble and miscible in ethanol.
Estonian: Trietüültsitraat on vesilahustuv ja seguneb etanooliga.
English: for conventional-release products (NLT 75% dissolved active substance within 45 minutes) and therefore experiences severe alteration, leading to an uncontrolled rapid release of the majority of the active substance.
Estonian: Lahustumiskatsete tulemused näitavad, et ravimvorm on Euroopa Farmakopöa järgi toimeainet tavapäraselt vabastavate ravimite piirides (45 minuti jooksul lahustub vähemalt 75% toimeainest) ja seetõttu on vabanemine ettenähtust tunduvalt teistsugune, põhjustades toimeainest enamiku kontrollimatu kiire vabastamise.
English: Notification of a referral for arbitration, under Article 29(4) of Directive 2001/83/EC as amended, to the CHMP was made by Denmark on 30 October 2009.
Estonian: 30. oktoobril 2009 tegi Taani muudetud direktiivi 2001/83/EÜ artikli 29 lõike 4 kohaselt inimravimite komiteele vahekohtumenetluse esildise.
English: During the assessment, major issues on safety were raised by Germany and the United Kingdom, hence the procedure was referred to CMD(h), under Article 29, paragraph 1 of Directive 2001/83/EC, as amended.
Estonian: Hindamise käigus tõstatasid Saksamaa ja Ühendkuningriik olulised ohutusküsimused, mille tõttu tehti muudetud direktiivi 2001/83/EÜ artikli 29 lõike 1 kohane esildis inimravimite komitee vastastikuse tunnustamise ja detsentraliseeritud menetluste koordineerimisrühmale.
English: Following a request from the European Commission, in September 2010 the CHMP further considered, in light of the benefit-risk balance and the requirements of article 24(2) of Directive 2001/83/EC as amended, the recommendation previously adopted for the product.
Estonian: Pärast Euroopa Komisjoni taotlust arutas inimravimite komitee 2010. aasta septembris veel kord ravimi jaoks varem vastuvõetud soovitust, võttes arvesse kasulikkuse ja riski suhet ning muudetud direktiivi 2001/83/EÜ artikli 24 lõike 2 nõudeid.
English: At the end of the CMD(h) procedure, and since there could be no agreement the procedure was referred to the CHMP.
Estonian: Et koordineerimisrühma menetlusega kokkulepet ei saavutatud, tehti esildis inimravimite komiteele.
English: It is noted that the product already contains a specific contraindication for concomitant intake of alcohol.
Estonian: Märgitakse, et ravimi tarvitamine alkoholiga samal ajal on konkreetselt vastunäidustatud.
English: • The Committee considered the procedure under Article 29(4) of Directive 2001/83/EC, as amended for Ethirfin and associated names,
Estonian: • inimravimite komitee vaatas läbi menetluse muudetud direktiivi 2001/83/EÜ artikli 29 lõike 4 kohaselt tehtud esildise Ethirfini ja sarnaste nimetuste kohta;
English: Having considered the overall submitted data provided by the MAH, the CHMP concluded that
Estonian: Inimravimite komitee kaalus müügiloa hoidja esitatud kõiki andmeid ja tegi järgmised järeldused:
English: This effect is known as ‘dose-dumping'.
Estonian: Sellist toimet nimetatakse annuse äkiliseks vabanemiseks.
English: The CHMP therefore recommended the non-renewal of the marketing authorisation in line with article 24(2) of Directive 2001/83/EC as amended.
Estonian: Inimravimite komitee soovitas seetõttu muudetud direktiivi 2001/83/EÜ artikli 24 lõike 2 kohaselt jätta müügiluba pikendamata.
English: • The Committee considered that the dissolution profile of Ethirfin and associated names is significantly affected in the presence of alcohol, leading to an uncontrolled rapid release of the majority of the active substance, therefore the product exhibits a significant interaction with alcohol with potentially significant clinical effects (e.g. respiratory depression and death),
Estonian: • komitee arvestas, et Ethirfini ja sarnaste nimetuste lahustumisprofiili mõjutab oluliselt ka kokkupuude alkoholiga, mis põhjustab enamiku toimeaine kiire ja kontrollimatu vabanemise.
English: This film acts as a membrane allowing the diffusion of the active substance depending on its permeability.
Estonian: Kile toimib membraanina, mis reguleerib toimeaine difusiooni.
English: • In addition, the dissolution profile of Ethirfin is significantly affected in the presence of alcohol, leading to an uncontrolled rapid release of the majority of the active substance, and therefore the product exhibits a significant interaction with alcohol with potentially significant clinical effects (e.g. respiratory depression and death),
Estonian: Selle tõttu on ravimil märkimisväärne koostoime alkoholiga, millega kaasnevad potentsiaalselt märkimisväärsed kliinilised tagajärjed (nt respiratoorne depressioon ja surm);
English: If pain persists for more than 12 hours after medical examination, the doctor should be contacted again.
Estonian: Kui valu püsib pärast arstlikku kontrolli üle 12 tunni, tuleb pöörduda uuesti arsti poole.
English: The repeated dose vaccination often gave slightly better results than the single vaccination.
Estonian: Kahe annusega vaktsineerimisel saadi sageli veidi paremaid tulemusi kui ühe annusega vaktsineerimisel.
English: In the future, if the animals are exposed to the virus or the bacteria the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad viiruse või bakteritega hiljem uuesti kokku, reageerib immuunsüsteem kiiremini.
English: Further information on Porcilis PCV M Hyo can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Lisateave Porcilis PCV M Hyo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: In three of the studies there was a third similar-sized group of pigs that were vaccinated using the two-dose schedule.
Estonian: Kolmes uuringus oli ka kolmas sarnase suurusega rühm põrsaid, keda vaktsineeriti kahe annusega vaktsineerimisskeemi järgi.
English: The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha inimtoiduks tarvitada.
English: The European Medicines Agency decided that Porcilis PCV M Hyo's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Porcilis PCV M Hyo kasulikkus on suurem, kui sellega kaasnevad riskid, ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: Porcilis PCV M Hyo is an emulsion containing mineral oil.
Estonian: Porcilis PCV M Hyo on mineraalõli sisaldav emulsioon.
English: For more information about using Porcilis PCV M Hyo, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate Porcilis PCV M Hyoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: The vaccine is given to pigs from three days of age as two injections into the neck muscle at least 18 days apart, or from three weeks of age as a single injection into the neck muscle.
Estonian: Vaktsiini manustatakse sigadele alates kolmandast elupäevast kahe vähemalt 18päevase vahega süstena kaelalihasesse või alates kolmandast elunädalast ühe süstena kaelalihasesse.
English: This will help protect the pigs against porcine circovirus and Mycoplasma hyopneumoniae infections.
Estonian: See aitab kaitsta sigu nakkuste eest, mida põhjustavad sigade tsirkoviirus ja bakter Mycoplasma hyopneumoniae.
English: Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger - this could result in the loss of the finger if prompt medical attention is not given.
Estonian: Juhuslik enesesüstimine võib põhjustada tugevat valu ja turset, eriti kui süst satub liigesesse või sõrme.
English: The two-dose vaccination schedule is recommended when PCV2 and/or Mycoplasma hyopneumoniae infections occur early.
Estonian: Kahe annusega vaktsineerimisskeemi soovitatakse kasutada siis, kui PCV2 ja/või Mycoplasma hyopneumoniae nakkused tekivad vara.
English: The most common side effect (seen in more than 1 in 10 pigs) with Porcilis PCV M Hyo is a short-lived increase in body temperature of up to 2 °C on the day of vaccination.
Estonian: Porcilis PCV M Hyo kõige sagedam kõrvalnäht (esinenud enam kui 1 seal 10st) on lühiajaline kehatemperatuuri tõus (kuni 2 °C) vaktsineerimispäeval.
English: • Infection with the bacterium Mycoplasma hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia.
Estonian: • Bakteri Mycoplasma hyopneumoniae nakkus põhjustab sigadel ensootilist pneumooniat
English: Other information about Porcilis PCV M Hyo
Estonian: Muu teave Porcilis PCV M Hyo kohta
English: The field studies showed that both single and repeated vaccination with Porcilis PCV M Hyo reduced PCV2 levels in the blood and the severity of lung damage (lesions) caused by Mycoplasma hyopneumoniae as well as the loss of daily weight gain during the finishing period (the fattening period prior to slaughter).
Estonian: Väliuuringutes tõendati, et ühekordne ja korduv vaktsineerimine Porcilis PCV M Hyoga vähendasid PCV2 sisaldust veres ning Mycoplasma hyopneumoniae tekitatud kopsukahjustuse raskust (haiguskoldeid kopsus) ja igapäevase kaaluiibe vähenemist nuumaperioodil (tapaeelne nuumamine).
English: The vaccine contains small amounts of a protein from PCV2 and whole Mycoplasma hyopneumoniae bacteria that have been killed (inactivated) so that they do not cause disease.
Estonian: Vaktsiin sisaldab väikestes kogustes PCV2 valku ja bakteri Mycoplasma hyopneumoniae tervikrakke, mis on inaktiveeritud (surmatud) ja ei põhjusta seetõttu haigestumist.
English: Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae.
Estonian: Porcilis PCV M Hyo on veterinaarvaktsiin, mida kasutatakse sigade kaitsmiseks kahe eri nakkuse eest, mida põhjustavad sigade tsirkoviirus ja Mycoplasma hyopneumoniae.
English: The effectiveness of Porcilis PCV M Hyo was investigated in 10 field studies involving pig farms where signs of PCV2 and/or Mycoplasma hyopneumoniae infections had been detected.
Estonian: Porcilis PCV M Hyo efektiivsust uuriti kümnes väliuuringus, milles osalesid seafarmid, kus loomadel oli tuvastatud PCV2 ja/või Mycoplasma hyopneumoniae nakkuse sümptomeid.
English: Porcilis PCV M Hyo contains the adjuvants light mineral oil and aluminium hydroxide to enhance the immune response.
Estonian: Porcilis PCV M Hyo sisaldab immuunvastuse tugevdamiseks adjuvantidena kerget mineraalõli ja alumiiniumhüdroksiidi.
English: Porcilis PCV M Hyo received a marketing authorisation valid throughout the EU for Porcilis PCV M Hyo on 7 November 2014.
Estonian: Porcilis PCV M Hyo müügiluba, mis kehtib kogu Euroopa Liidus, anti 7. novembril 2014.
English: When Porcilis PCV M Hyo is given to pigs the animals' immune system recognises the virus protein and bacteria as ‘foreign' and makes antibodies against them.
Estonian: Kui sigadele manustatakse Porcilis PCV M Hyot, peab immuunsüsteem viiruse valku ja baktereid võõraks ja toodab nende vastu antikehi.
English: Porcilis PCV M Hyo is a vaccine.
Estonian: Porcilis PCV M Hyo on vaktsiin.
English: Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.
Estonian: Porcilis PCV M Hyo sisaldab sigade tsirkoviiruse tüüp 2 (PCV2) alaühiku antigeeni (viiruse teatud osast saadud valku) ja inaktiveeritud (surmatud) Mycoplasma hyopneumoniae bakteri tüve.
English: What is Porcilis PCV M Hyo and what is it used for?
Estonian: Mis on Porcilis PCV M Hyo ja milleks seda kasutatakse?
English: In each study around 300 suckling piglets were vaccinated once with Porcilis PCV M Hyo and a second similar-sized group of piglets received a dummy injection.
Estonian: Igas uuringus vaktsineeriti ligikaudu 300 piimapõrsast üks kord Porcilis PCV M Hyoga.
English: The withdrawal period for Porcilis PCV M Hyo is zero days.
Estonian: Porcilis PCV M Hyo keeluaeg on 0 päeva.
English: How does Porcilis PCV M Hyo work?
Estonian: Kuidas Porcilis PCV M Hyo toimib?
English: Laboratory studies in pigs showed that with two-dose vaccination the vaccine had its full effect against PCV2 by 18 days after first injection and against Mycoplasma hyopneumoniae by three weeks after the second injection, whilst with single-dose vaccination the vaccine had its full effect against PCV2 by two weeks and against Mycoplasma hyopneumoniae by four weeks.
Estonian: Sigadel tehtud laboriuuringutes tõendati, et kahe annusega vaktsineerimisel saavutas vaktsiin maksimaalse toime PCV2 vastu 18. päevaks pärast esimest vaktsineerimist ja Mycoplasma hyopneumoniae vastu kolmandaks nädalaks pärast teist vaktsineerimist.
English: Porcilis PCV M Hyo (Porcine circovirus and Mycoplasma hyopneumoniae vaccine, inactivated)
Estonian: Porcilis PCV M Hyo (Sigade tsirkoviiruse ja Mycoplasma hyopneumoniae vaktsiin, inaktiveeritud) Porcilis PCV M Hyo ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: With two-dose vaccination, protection against PCV2 starts at 18 days after the first injection and for Mycoplasma hyopneumoniae it starts 3 weeks after the second injection.
Estonian: Kahe annusega vaktsineerimise korral tekib PCV2-vastane kaitse 18 päeva pärast esimest vaktsineerimist ja Mycoplasma hyopneumoniae vastane kaitse tekib 3 nädalat pärast teist vaktsineerimist.
English: • Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
Estonian: kehamassi langus või kasvupeetus, lümfisõlmede suurenemine, hingamisraskused, kõhulahtisus,
English: For both vaccination schedules protection lasts for 22 weeks after (the last) injection for PCV2 and for 21 weeks after (the last) injection for Mycoplasma hyopneumoniae.
Estonian: Mõlema vaktsineerimisskeemi korral kestab kaitse PCV2 nakkuse vastu 22 nädalat pärast (viimast) vaktsineerimist ja Mycoplasma hyopneumoniae nakkuse vastu 21 nädalat pärast (viimast) vaktsineerimist.
English: With both vaccination schedules protection lasted 22 weeks after (the last) injection for PCV2 and 21 weeks after (the last) injection for Mycoplasma hyopneumoniae.
Estonian: Mõlema vaktsineerimisskeemi korral kestis kaitse PCV2 vastu 22 nädalat pärast (viimast) vaktsineerimist ja Mycoplasma hyopneumoniae vastu 21 nädalat pärast (viimast) vaktsineerimist.
English: With single-dose vaccination, protection against PCV2 starts at two weeks after the injection and for Mycoplasma hyopneumoniae it starts four weeks after the injection.
Estonian: Ühe annusega vaktsineerimise korral tekib kaitse PCV2 vastu kaks nädalat pärast vaktsineerimist ja Mycoplasma hyopneumoniae vastu neli nädalat pärast vaktsineerimist.
English: What are the risks associated with Porcilis PCV M Hyo?
Estonian: Mis riskid Porcilis PCV M Hyoga kaasnevad?
English: Porcilis PCV M Hyo is available as an injection and can only be obtained with a prescription.
Estonian: Vaktsiini Porcilis PCV M Hyo turustatakse süstelahusena ja see on retseptivaktsiin.
English: What benefits of Porcilis PCV M Hyo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Porcilis PCV M Hyo kasulikkus?
English: An overview of Porcilis PCV M Hyo and why it is authorised in the EU
Estonian: Porcilis PCV M Hyo Euroopa Liidus heakskiitmise põhjused
English: How is Porcilis PCV M Hyo used?
Estonian: Kuidas vaktsiini Porcilis PCV M Hyo kasutatakse?
English: The median follow-up duration was 22.9 months.
Estonian: Jälgimisaja mediaan oli 22,9 kuud.
English: Hazard Ratio [95% CI]
Estonian: Riskitiheduste suhe [95% CI]
English: Placebo (N = 3,264) n (%)
Estonian: Platseebo (N=3264) n (%)
English: - Severe hypotension (< 90/50 mmHg).
Estonian: - Raske hüpotensioon (<90/50 mm Hg).
English: Women that need treatment with ivabradine should stop breastfeeding, and choose for another way of feeding their child.
Estonian: Ravi ivabradiiniga vajavad naised peavad lõpetama imetamise ning valima oma lapsele teise toitmisviisi.
English: Food delayed absorption by approximately 1 hour, and increased plasma exposure by 20 to 30%.
Estonian: Toit aeglustas imendumist ligikaudu 1 tunni võrra ja suurendas plasma ekspositsiooni 20…30% võrra.
English: Hypromellose Titanium dioxide Macrogol 400
Estonian: Õhuke polümeerkate Hüpromelloos Titaandioksiid Makrogool 400
English: Ivabradine Zentiva is not intended for use in children and adolescents younger than 18 years.
Estonian: Ivabradine Zentiva ei ole mõeldud kasutamiseks lastel ja alla 18-aastastel noorukitel.
English: If you think that the effect of Ivabradine Zentiva is too strong or too weak, talk to your doctor or pharmacist.
Estonian: Kui teil on tunne, et Ivabradine Zentiva toime on liiga tugev või liiga nõrk, pidage nõu oma arsti või apteekriga.
English: Frequency Preferred Term
Estonian: Eelistatud termin
English: It is used in adult patients who do not tolerate or cannot take heart medicines called beta-blockers.
Estonian: Seda kasutatakse täiskasvanud patsientidel, kes ei talu või ei saa võtta südameravimeid, mida nimetatakse beetablokaatoriteks.
English: The total clearance is about 400 mL/min and the renal clearance is about 70 mL/min.
Estonian: Kogukliirens on ligikaudu 400 ml/min ning neerukliirens on ligikaudu 70 ml/min.
English: However, in postmarketing experience, cases of impaired driving ability due to visual symptoms have been reported.
Estonian: Siiski on turuletulekujärgse kogemuse käigus teatatud autojuhtimise võime halvenemisest nägemishäirete tõttu.
English: These episodes occurred most frequently shortly after blood pressure treatment was modified, were transient, and did not affect the treatment effect of ivabradine.
Estonian: Need episoodid ilmnesid kõige sagedamini kohe pärast seda, kui vererõhu ravi oli muudetud, olid üldjuhul mööduvad ning ei mõjutanud ivabradiini ravitoimet.
English: Pharmacotherapeutic group: Cardiac therapy, other cardiac preparations; ATC code: C01EB17.
Estonian: Farmakoterapeutiline rühm: südamehaiguste ravi, teised südamesse toimivad preparaadid, ATC-kood: C01EB17.
English: Very common Luminous phenomena (phosphenes) Common
Estonian: Helendav nägemisfenomen (fosfeenid)
English: Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble (> 10 mg/mL).
Estonian: Füsioloogilistes tingimustes vabaneb ivabradiin tabletivormist kiiresti ning lahustub vees väga kergesti (>10 mg/ml).
English: OPA/Alu/PVC-Alu blisters, paper carton.
Estonian: OPA/Alu/PVC//Alu blistrid, kartongkarp.
English: Ivabradine has been studied in clinical trials involving nearly 45,000 participants.
Estonian: Ivabradiini on uuritud ligikaudu 45 000 osalejat hõlmavates kliinilistes uuringutes.
English: In dogs given ivabradine (doses of 2, 7 or 24 mg/kg/day) for one year, reversible changes in retinal function were observed but were not associated with any damage to ocular structures.
Estonian: Koertel, kes said ivabradiini (annuses 2, 7 või 24 mg/kg/ööpäevas) ühe aasta jooksul, leiti pöörduvad võrkkesta funktsiooni muutused, samas ei olnud need seostatavad ühegi silma struktuuri kahjustusega.
English: The results on the primary endpoint are mainly driven by the heart failure endpoints, hospitalisation for worsening heart failure (absolute risk reduced by 4.7%) and deaths from heart failure (absolute risk reduced by 1.1%).
Estonian: Esmase tulemusnäitaja tulemused tulenevad peamiselt südamepuudulikkuse tulemusnäitajast, südamepuudulikkuse halvenemisest tulenevast hospitaliseerimisest (absoluutne risk vähenes 4,7%) ja südamepuudulikkuse tagajärjel tekkinud surmajuhtudest (absoluutne risk vähenes 1,1%).
English: If there is no improvement in symptoms of angina within 3 months after start of treatment, treatment of ivabradine should be discontinued.
Estonian: Kui stenokardia sümptomid ei parane 3 kuu jooksul pärast ravi alustamist, tuleb ravi ivabradiiniga katkestada.
English: The environmental risk assessment of ivabradine has been conducted in accordance to European guidelines on ERA.
Estonian: Keskkonnariski hindamine Ivabradiini keskkonnariski hindamine on teostatud vastavalt Euroopa keskkonnariski hindamise juhenditele.
English: 74 received ivabradine (ratio 2:1).
Estonian: 74 patsienti said ivabradiini (suhe 2:1).
English: Bradycardia was reported by 3.3% of patients particularly within the first 2 to 3 months of treatment initiation.
Estonian: Bradükardia tekkis 3,3% patsientidest ja seda eriti esimese 2…3 ravikuu jooksul.
English: No data are available in patients with creatinine clearance below 15 mL/min.
Estonian: Puuduvad andmed patsientide kohta, kellel kreatiniini kliirens on alla 15 ml/min.
English: A specific study to assess the possible influence of ivabradine on driving performance has been performed in healthy volunteers where no alteration of the driving performance was evidenced.
Estonian: Ivabradiini mõju autojuhtimise võimele on uuritud spetsiaalses uuringus tervetel vabatahtlikel, kus muutusi autojuhtimise võimes ei täheldatud.
English: - Cardiogenic shock.
Estonian: - Kardiogeenne šokk.
English: Other long-term repeat dose and carcinogenicity studies revealed no clinically relevant changes.
Estonian: Teistes pikaajalistes korduvtoksilisuse ja kartsinogeensuse uuringutes kliiniliselt olulisi muutusi ei täheldatud.
English: Patients received standard care including beta-blockers (89%), ACE inhibitors and/or angiotensin II antagonists (91%), diuretics (83%), and anti-aldosterone agents (60%).
Estonian: Patsiendid said standardravi, sealhulgas beetablokaatoreid (89%), AKE-inhibiitoreid ja/või angiotensiin II antagoniste (91%), diureetikume (83%) ja aldosterooni blokeerivaid aineid (60%).
English: They generally occur within the first two months of treatment after which they may occur repeatedly and resolve during or after treatment.
Estonian: See ilmneb tavaliselt 2 esimese ravikuu jooksul, peale mida võib see korduda ja kaduda ravi ajal või peale ravi.
English: - Unstable or acute heart failure.
Estonian: - Ebastabiilne või äge südamepuudulikkus.
English: - Sick sinus syndrome.
Estonian: - Sick-sinus sündroom.
English: - Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6).
Estonian: - Rasedus, imetamine ja fertiilses eas naised, kes ei kasuta efektiivseid rasestumisvastaseid meetmeid (vt lõik 4.6).
English: Ivabradine Zentiva may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see “Possible side effects”).
Estonian: Ivabradine Zentiva võib põhjustada ajutist helendava nägemise fenomeni (ajutine eredus nägemisväljas, vt “Võimalikud kõrvaltoimed”).